IOPE, a brand under Amorepacific, announced on the 3rd that it will launch in Sephora, the world's largest beauty retail channel. Based on its partnership with Sephora, IOPE plans to expand its global business in the North American market, focusing on anti-aging products.
Starting this month, IOPE will be available in Sephora offline stores and online platforms across the United States, introducing its "Clinical Grade" skincare products.
The key products for the North American market are the "XMD Stem3 Clinical Recovery Serum" and "Retinol Retijection Serum." The company explained that both products have been verified for efficacy through human application tests comparing them one-to-one with specialized treatments. The XMD Stem3 Clinical Recovery Serum contains 92.3% PDRN H.A.™ complex, demonstrating improvements in hydration and pore refinement. The Retinol Retijection Serum delivers retinol through a structure of 3 million spicules (natural needle structures), showing improvements in elasticity, wrinkles, and pores.
IOPE will also launch additional anti-aging products including the "Retinol Super Bounce Serum," "Vitamin C Expert 40% Mask Concentrate," and "PDRN Caffeine Shot Ampoule."
Launched in 1996, IOPE has developed anti-aging products based on retinol stabilization technology. Over 30 years, the brand has secured 26 patents and published 43 research papers.
"IOPE has built its competitiveness based on retinol and dermatological research technology accumulated over 30 years," said Kim Jong-ha, Executive Vice President of Amorepacific's Active Beauty Unit. "With this Sephora launch as a turning point, we will establish our position as a clinical-grade skincare brand in the North American market as well."